AGM
SPRY icon

Alpine Global Management’s ARS Pharmaceuticals SPRY Stock Holding History

Alpine Global Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,435
Closed -$199K – 437
2024
Q2 		$199K Buy
+23,435
New +$208K 0.03% 310

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alpine Global Management's SPRY Position: Q3 2024 in Review

Alpine Global Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2024, closing a stake of 23,435 shares — an estimated $199K sold.

Alpine Global Management first reported a position in SPRY in Q2 2024 and held it in 1 quarter. The position peaked at $199K in Q2 2024. 150 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Alpine Global Management reported no remaining ARS Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 23,435 ARS Pharmaceuticals shares in Q3 2024, an estimated $199K.
  • Alpine Global Management first reported a position in ARS Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's ARS Pharmaceuticals position peaked at $199K in Q2 2024.
  • 150 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.